超声内镜引导下肝肠吻合术作为通道以实现对手术改变解剖结构患者良性胆道疾病的确定性顺行治疗
回顾性分析20例手术改变解剖结构的良性胆道梗阻患者,接受超声内镜引导下肝肠吻合术(EUS-HE)并顺行治疗;技术均成功,18例完成确定性治疗,3例轻度不良事件,无严重不良事件或死亡;作者认为EUS-HE安全有效,可作为其他内镜方法的可行替代。
要点
- EUS-HE在手术改变解剖结构的良性胆道梗阻中技术可行,可建立顺行治疗通道。
- 20例中18例通过肝肠吻合通道完成确定性顺行内镜治疗,平均2.7次操作。
- 3例发生轻度不良事件需住院少于3晚,无严重不良事件和死亡。
核心结论
- EUS-HE对手术改变解剖结构的良性胆道梗阻患者安全有效,可建立通道实现确定性顺行治疗,是该人群其他内镜方法的可行替代。
研究设计与样本
- 回顾性综述,纳入3年期间在三级中心由1位内镜医师连续治疗的20例手术改变解剖结构且良性胆道梗阻并接受EUS-HE的患者。
主要发现
- 研究期间37例接受EUS-HE,其中24例为良性疾病,20例手术改变解剖结构者纳入分析(15例女性,平均年龄62岁)。
- 手术改变解剖结构包括9例Roux-en-Y胃旁路术、6例Roux-en-Y肝肠吻合术、2例Billroth II式手术和3例Whipple手术。
- ERC指征为胆总管结石(n=8)、良性术后狭窄(n=7)、慢性胰腺炎(n=3)、炎性狭窄(n=1)和治疗胆漏(n=1);5例既往球囊小肠镜辅助ERC失败。
- 入路为经胃15例、经空肠5例;所有病例均穿刺左肝管分支,平均直径7.8 mm;支架中位长度80 mm,直径8或10 mm。
- 18例通过肝肠吻合通道完成顺行确定性内镜治疗,平均2.7次操作以解决结石和/或下游狭窄;17例在平均91天后移除肝肠吻合支架,无不良事件。
临床怎么用
- 作者认为EUS-HE对手术改变解剖结构的良性胆道梗阻安全有效,可建立通道实现确定性顺行治疗,是该人群其他内镜方法的可行替代。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: EUS-guided hepaticoenterostomy (EUS-HE) usually is reserved for palliation of malignant biliary obstruction after failed endoscopic retrograde cholangiography (ERC) or inaccessible biliary tree in surgically altered anatomy (SAA). We describe the outcome of EUS-HE and antegrade therapy for benign biliary disease in patients with SAA. METHODS: Retrospective review of 20 consecutive patients with surgically altered anatomy and benign biliary obstruction who underwent EUS-HE performed by 1 endoscopist at a tertiary-care center over a 3-year period. RESULTS: During the study period, 37 patients underwent EUS-HE; 24 for benign disease. Of these, 20 patients had SAA and were analyzed (15 women, mean age, 62 years). SAA consisted of 9 Roux-en-Y gastric bypasses, 6 Roux-en-Y hepaticojejunostomy, 2 Billroth II procedures, and 3 Whipple procedures. Indications for ERC were common bile duct stones (n = 8), benign postoperative strictures (n = 7), chronic pancreatitis (n = 3), inflammatory stricture (n = 1), and treatment of a bile leak (n = 1). Five patients had previously failed balloon enteroscopy-assisted ERCs. The approach was transgastric in 15 and transjejunal in 5. In all cases, a branch of the left hepatic duct with a mean diameter of 7.8 mm was accessed. Median stent length was 80 mm, with diameters of 8 or 10 mm. Antegrade, definitive endoscopic therapy via the HE was performed in 18 patients, with an average of 2.7 procedures performed for resolution of stones and/or downstream strictures. HE stents were removed in 17 patients after a mean of 91 days without adverse events. Three patients experienced mild adverse events (1 with postprocedural pancreatitis after placement of a 10F transpapillary stent, 1 with postprocedural abdominal pain, and 1 with postprocedural cholangitis) requiring hospitalization for fewer than 3 nights; no severe adverse events occurred. The average postprocedural hospital stay was 1.3 days. No deaths occurred during follow-up. CONCLUSIONS: EUS-HE is safe and effective in the management of benign biliary obstruction in patients with surgically altered anatomy. It creates a portal to allow definitive, antegrade therapy and is a viable alternative to other endoscopic methods in this patient population.
引用
- James TW, Fan YC, Baron TH, et al. EUS-guided hepaticoenterostomy as a portal to allow definitive antegrade treatment of benign biliary diseases in patients with surgically altered anatomy. Gastrointest Endosc. 2018. PMID: 29729226. doi:10.1016/j.gie.2018.04.2353
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。